Back to User profile » Dr Margherita Andretta

Papers published by Dr Margherita Andretta:


Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug–Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA)

Fagiuoli S, Toniutto P, Coppola N, Ancona DD, Andretta M, Bartolini F, Ferrante F, Lupi A, Palcic S, Rizzi FV, Re D, Alvarez Nieto G, Hernandez C, Frigerio F, Perrone V, Degli Esposti L, Mangia A

Therapeutics and Clinical Risk Management 2023, 19:57-65

Published Date: 18 January 2023

Evaluation of the Therapeutic Pattern and Pharmaco-Utilization in Hypercholesterolemic Patients Treated with Statins: A Retrospective Study on Italian Real-World Data

Perrone V, Giacomini E, Sangiorgi D, Andretta M, Bartolini F, Lupi A, Ferrante F, Palcic S, Re D, Degli Esposti L

Risk Management and Healthcare Policy 2022, 15:1483-1489

Published Date: 28 July 2022

Analysis of Patients with Focal Epilepsy and Drug-Resistant Epilepsy in Italy: Evaluation of Their Characteristics, Therapeutic Pathway and the Consumption of Healthcare Resources

Perrone V, Veronesi C, Dovizio M, Ancona DD, Andretta M, Bartolini F, Cavaliere A, Chinellato A, Ciaccia A, Cillo M, De Francesco A, Enieri N, Ferrante F, Gentile S, Procacci C, Ubertazzo L, Vercellone A, Lucatelli D, Procaccini M, Degli Esposti L

ClinicoEconomics and Outcomes Research 2022, 14:513-521

Published Date: 28 July 2022

Direct Healthcare Costs by Level of Adherence of a Real-World Population of Statin Users in Italy

Degli Esposti L, Veronesi C, Ancona DD, Andretta M, Bartolini F, Drei A, Lupi A, Palcic S, Re D, Rizzi FV, Giacomini E, Perrone V

ClinicoEconomics and Outcomes Research 2022, 14:139-147

Published Date: 10 March 2022

Healthcare Resource Consumption and Related Costs of Patients Estimated with Treatment-Resistant Depression in Italy

Perrone V, Sangiorgi D, Andretta M, Ducci G, Forti B, Francesa Morel PC, Gambera M, Maina G, Mencacci C, Mennini FS, Zanalda E, Degli Esposti L

ClinicoEconomics and Outcomes Research 2021, 13:629-635

Published Date: 5 July 2021

Italian Real-World Analysis of a Tyrosine Kinase Inhibitor Administration as First- or Second-Line of Therapy in Patients with Chronic Myeloid Leukemia

Perrone V, Giacomini E, Andretta M, Arenare L, Cillo MR, Latini M, Mecozzi A, Pagliaro R, Vercellone A, Degli Esposti L

Therapeutics and Clinical Risk Management 2021, 17:617-622

Published Date: 8 June 2021